TMDX Stock Forecast & Price Target

TransMedics Group is positioned for a 2H’26/2027 inflection as transplant-volume recovery, liver share gains, and a likely acceleration from ENHANCE Part B, DENOVO, CHOPS, and OCS kidney could convert a 2026 spending cycle into stronger revenue growth and operating leverage. The company’s core OCS platform is addressing a nearly $8B opportunity while expanding organ utilization in a market where 75% to 80% of donor organs are currently unused, supporting a differentiated growth story rather than a pure volume recovery trade. With 2Q26 revenue estimated at $195M versus $183M consensus, 2026 revenue around $749M, and shares trading at 3.3x sales versus a 2-year average of 5.9x, the setup remains attractive if execution continues.

TransMedics Group is facing a negative fundamental setup because its OCS platform still depends on winning broader physician adoption away from entrenched cold-storage practices, while management itself expects acceptance outside DENOVO centers to hinge on trial evidence rather than enthusiasm. The business also carries concentrated regulatory, reimbursement, and customer risk, with no specific U.S. reimbursement code, limited commercialization experience, and quarterly revenue exposed to unpredictable transplant volumes, all of which could pressure growth and pricing as machine-perfusion competition intensifies. Financially, 1Q26 showed weak gross margin, elevated adjusted operating expenses of $83M, and interest expense rising to $7.2M per quarter, while FY26 total interest expense was lifted to $28.8M, reinforcing a view of limited operating leverage and execution risk.